Smart Scoliosis Developments is advancing a superelastic nitinol implant for adolescent idiopathic scoliosis. The concept is promising; the evidence, and two FDA-cleared rivals, are the catch.
There is a stubborn gap in adolescent idiopathic scoliosis (AIS) that the industry has spent two decades trying to close: the space between the brace, which teenagers resist wearing, and spinal fusion, which trades a straight spine for a stiff one. A Madrid company believes it has found a way in.
Smart Scoliosis Developments, based at the Parque Científico de Madrid on the Universidad Autónoma’s Cantoblanco campus, is advancing ProFlex Spine, a minimally invasive, non-fusion procedure for AIS. The company describes it as an “active internal brace,” a phrase worth unpacking, because it is not a brace at all. ProFlex is a surgical implant. What the company means is that, unlike fusion, the device is meant to guide and modulate spinal growth while preserving motion, doing the corrective job a rigid orthosis does without the compliance problem that quietly undermines bracing in this age group.
The hardware is a superelastic nitinol rod, branded SMROD, developed with the Universidad Politécnica de Madrid and described as delivering three-dimensional correction through a reproducible, minimally invasive technique. The appeal of a shape-memory alloy here is real: nitinol can hold a corrective force across a wide range of deformation and recover its form, which in theory lets the implant keep working with the spine as the patient grows rather than against it. That is an elegant idea on paper. The unknown is how the rod behaves inside a living, lengthening spine over three, five and ten years, which is precisely the question a bench model and a marketing page cannot answer. Conceptually, ProFlex belongs to the fusionless family that vertebral body tethering (VBT) put on the map. The premise is shared: in a growing spine, modulate growth and preserve mobility rather than locking segments together. Where ProFlex departs is the mechanics, leaning on smart-alloy behaviour rather than a cord-and-screw or ratcheting construct. That is genuinely differentiated. Differentiation, though, is not evidence.
The competitive field
ProFlex is not entering an empty room. Two non-fusion devices already hold US clearance, both granted in the same month, August 2019. The better known is Highridge Medical’s Tether (the spine business spun out of ZimVie and now privately held under H.I.G. Capital), the anterior VBT system the FDA approved as the first of its kind; prospective multicenter series are now reporting two-year outcomes across more than a hundred patients. The other is ApiFix’s MID-C, a posterior, self-adjusting rod acquired in 2020 by Nasdaq-listed OrthoPediatrics, which folds it into a deformity portfolio that also includes the VerteGlide guided-growth implant. The detail that should give Smart Scoliosis pause is the branding: ApiFix has marketed MID-C as an “internal brace” for years, which is the exact positioning ProFlex is now reaching for. Behind those two sit the deformity incumbents, Medtronic, Globus Medical (now carrying NuVasive’s tethering programme) and Stryker, any of which can move quickly once a fusionless approach proves itself commercially. A Madrid startup with a nitinol rod is, for the moment, the smallest player in that room and the only one without a cleared product.
It is worth being precise about what “cleared” means here, because it cuts in two directions. Both US approvals came through the humanitarian device exemption, the pathway reserved for conditions affecting no more than 8,000 patients a year in the United States. The HDE is explicitly exempt from the effectiveness requirements of a full premarket approval; a sponsor must show the device is reasonably safe and offers probable benefit, not that it works at the standard a randomized trial would demand. So the two products ProFlex must out-argue did not clear a high efficacy bar to reach the market. That lowers the perceived wall. But it also tells you the entire fusionless category is still operating on thin, regulated-as-rare evidence, which is a caution as much as an opening.
Where the project stands
The honest answer on maturity is: early. Smart Scoliosis was recognised in the zero-to-three-year cohort of Madrid’s HealthStart programme, the bracket reserved for the youngest companies, and the SMROD patent is still in process. The company is simultaneously recruiting its first clinical-study patients and building the R&D bench around the device through an industrial doctorate and a Torres Quevedo postdoctoral contract. There is no published outcomes data, no patient-treated count in the public domain, and no CE mark or FDA clearance. This is a preclinical-to-first-clinical proposition supported largely by public grants and science-park incubation, not a commercial product.
The regulatory road ahead is also a different road from the one the US incumbents travelled. As an EU developer, Smart Scoliosis is looking at the European MDR, under which a long-term implantable spinal device sits in the highest risk class and requires clinical evidence assessed by a notified body before it can carry a CE mark. There is no humanitarian shortcut of quite the same shape in Europe, so the very dataset the company has yet to generate is the thing that unlocks its home market. One founding partner is an experienced spine surgeon linked to Hospital Universitario La Paz, bringing close to two decades of clinical and scientific work in the field, which lends the credibility these early stages live or die on. Credibility, however, is not the same thing as a dataset.
The evidence bar
And data is the whole question. The commercial message, correction “without the drawbacks of the brace,” lands hard, because brace non-compliance, discomfort and the emotional toll on adolescents are real and well documented. But bracing carries something ProFlex does not yet have. The landmark BrAIST trial established that adequate brace wear significantly lowers the risk of a curve progressing to the surgical threshold, with benefit rising the more hours the brace is worn. That is a high-quality result a newcomer has to respect. On the surgical side, VBT itself is still working through real-world complications, with revision and tether-breakage rates the literature continues to flag as material, and ApiFix’s early experience drew its own reoperation questions. The lesson for ProFlex is that a fusionless device is not judged on its first-day correction but on what survives years of growth and load.
For the investors and distributors, the diligence list writes itself: patients treated to date, initial Cobb correction in degrees, maintenance at 12, 24 and 36 months, complications, reintervention and implant-failure rates, overcorrection, the candidate profile, and head-to-head positioning against brace, VBT and fusion. Worth a second look, too, is the gap between the company’s headline market and its real one. Scoliosis is common, and Smart Scoliosis cites 16 million sufferers worldwide, but the progressive, surgery-bound subset these devices actually treat is a fraction of that figure, which is exactly why the US pathway for the category is a rare-disease exemption. The intended go-to-market is conventional and capital-light, with implants sold through local distributors and mandatory surgeon certification before anyone touches SMROD. That lowers the cost of entry but raises the bar on training and proctoring.
Spain rarely originates spine implant platforms, and Madrid’s innovation machinery has clearly gotten behind this one. That is worth watching. But watching is the operative word. The fusionless thesis is sound; whether ProFlex is the device that proves it in nitinol, against two cleared competitors and a row of incumbents, is a question only clinical data will answer. The moment that changes is the moment the first peer-reviewed correction-and-maintenance numbers land. Until then, this is a credible idea in search of its evidence.
About ProFlex Spine
ProFlex Spine is an initiative by Smart Scoliosis Developments to offer adolescents with idiopathic scoliosis a less invasive treatment option designed to better preserve their quality of life.https://proflexspine.com
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.